1. Home
  2. PWM vs APRE Comparison

PWM vs APRE Comparison

Compare PWM & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PWM
  • APRE
  • Stock Information
  • Founded
  • PWM 2018
  • APRE 2006
  • Country
  • PWM Hong Kong
  • APRE United States
  • Employees
  • PWM N/A
  • APRE N/A
  • Industry
  • PWM
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PWM
  • APRE Health Care
  • Exchange
  • PWM Nasdaq
  • APRE Nasdaq
  • Market Cap
  • PWM 12.4M
  • APRE 10.0M
  • IPO Year
  • PWM 2023
  • APRE 2019
  • Fundamental
  • Price
  • PWM $0.35
  • APRE $1.78
  • Analyst Decision
  • PWM
  • APRE Strong Buy
  • Analyst Count
  • PWM 0
  • APRE 2
  • Target Price
  • PWM N/A
  • APRE $15.50
  • AVG Volume (30 Days)
  • PWM 180.3K
  • APRE 51.1K
  • Earning Date
  • PWM 07-07-2025
  • APRE 08-11-2025
  • Dividend Yield
  • PWM N/A
  • APRE N/A
  • EPS Growth
  • PWM N/A
  • APRE N/A
  • EPS
  • PWM N/A
  • APRE N/A
  • Revenue
  • PWM $639,912.00
  • APRE $1,284,475.00
  • Revenue This Year
  • PWM N/A
  • APRE N/A
  • Revenue Next Year
  • PWM N/A
  • APRE N/A
  • P/E Ratio
  • PWM N/A
  • APRE N/A
  • Revenue Growth
  • PWM 83.60
  • APRE 33.27
  • 52 Week Low
  • PWM $0.31
  • APRE $1.41
  • 52 Week High
  • PWM $2.70
  • APRE $5.01
  • Technical
  • Relative Strength Index (RSI)
  • PWM 42.41
  • APRE 52.34
  • Support Level
  • PWM $0.33
  • APRE $1.48
  • Resistance Level
  • PWM $0.37
  • APRE $1.91
  • Average True Range (ATR)
  • PWM 0.03
  • APRE 0.16
  • MACD
  • PWM -0.00
  • APRE -0.00
  • Stochastic Oscillator
  • PWM 28.75
  • APRE 63.14

About PWM Prestige Wealth Inc.

Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Share on Social Networks: